273 related articles for article (PubMed ID: 8971023)
21. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
22. Induction of endogenous genes following infection of human endothelial cells with an E1(-) E4(+) adenovirus gene transfer vector.
Ramalingam R; Rafii S; Worgall S; Hackett NR; Crystal RG
J Virol; 1999 Dec; 73(12):10183-90. PubMed ID: 10559334
[TBL] [Abstract][Full Text] [Related]
23. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.
Brough DE; Hsu C; Kulesa VA; Lee GM; Cantolupo LJ; Lizonova A; Kovesdi I
J Virol; 1997 Dec; 71(12):9206-13. PubMed ID: 9371579
[TBL] [Abstract][Full Text] [Related]
24. Biology of E1-deleted adenovirus vectors in nonhuman primate muscle.
Zoltick PW; Chirmule N; Schnell MA; Gao GP; Hughes JV; Wilson JM
J Virol; 2001 Jun; 75(11):5222-9. PubMed ID: 11333904
[TBL] [Abstract][Full Text] [Related]
25. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
26. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors.
Kolls JK; Lei D; Odom G; Nelson S; Summer WR; Gerber MA; Shellito JE
Hum Gene Ther; 1996 Mar; 7(4):489-97. PubMed ID: 8800743
[TBL] [Abstract][Full Text] [Related]
27. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of CXCR4 gene expression in primary human endothelial cells following infection with E1(-)E4(+) adenovirus gene transfer vectors.
Ramalingam R; Worgall S; Rafii S; Crystal RG
Mol Ther; 2000 Oct; 2(4):381-6. PubMed ID: 11020354
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response.
Christ M; Lusky M; Stoeckel F; Dreyer D; Dieterlé A; Michou AI; Pavirani A; Mehtali M
Immunol Lett; 1997 Jun; 57(1-3):19-25. PubMed ID: 9232420
[TBL] [Abstract][Full Text] [Related]
30. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes.
Scaria A; Curiel DT; Kay MA
Gene Ther; 1995 Jun; 2(4):295-8. PubMed ID: 7552990
[TBL] [Abstract][Full Text] [Related]
31. Effects of first generation E1E3-deleted and second generation E1E3E4-deleted/modified adenovirus vectors on human endothelial cell death.
Jornot L; Petersen H; Lusky M; Pavirani A; Moix I; Morris ; Rochat T
Endothelium; 2001; 8(3):167-79. PubMed ID: 11824470
[TBL] [Abstract][Full Text] [Related]
32. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs.
Chirmule N; Hughes JV; Gao GP; Raper SE; Wilson JM
J Virol; 1998 Jul; 72(7):6138-45. PubMed ID: 9621078
[TBL] [Abstract][Full Text] [Related]
33. Differential influence of the E4 adenoviral genes on viral and cellular promoters.
Grave L; Dreyer D; Dieterle A; Leroy P; Michou AI; Doderer C; Pavirani A; Lusky M; Mehtali M
J Gene Med; 2000; 2(6):433-43. PubMed ID: 11199264
[TBL] [Abstract][Full Text] [Related]
34. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver.
Croyle MA; Chirmule N; Zhang Y; Wilson JM
Hum Gene Ther; 2002 Oct; 13(15):1887-900. PubMed ID: 12396620
[TBL] [Abstract][Full Text] [Related]
35. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
36. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
Thomas MA; Song R; Demberg T; Vargas-Inchaustegui DA; Venzon D; Robert-Guroff M
PLoS One; 2013; 8(10):e76344. PubMed ID: 24143187
[TBL] [Abstract][Full Text] [Related]
37. Designing E1 deleted adenoviral vector by homologous recombination.
Zamani A; Ghannad MS
Iran Biomed J; 2007 Jul; 11(3):199-202. PubMed ID: 18051781
[TBL] [Abstract][Full Text] [Related]
38. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.
Armentano D; Smith MP; Sookdeo CC; Zabner J; Perricone MA; St George JA; Wadsworth SC; Gregory RJ
J Virol; 1999 Aug; 73(8):7031-4. PubMed ID: 10400804
[TBL] [Abstract][Full Text] [Related]
39. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo.
Klonjkowski B; Gilardi-Hebenstreit P; Hadchouel J; Randrianarison V; Boutin S; Yeh P; Perricaudet M; Kremer EJ
Hum Gene Ther; 1997 Nov; 8(17):2103-15. PubMed ID: 9414258
[TBL] [Abstract][Full Text] [Related]
40. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
